Brian J. Druker

Hematology · 2000–2018

A researcher in the Science corpus: 28 papers; trusts 6 researchers and is trusted by 9 researchers here, as inferred from the citation graph.

Subfields

• Hematology — 130 citations into it; #15 of 225 by trust here, #2 by citations
• Genetics — 104 citations into it; #2,623 of 6,854 by trust here, #247 by citations
• Rheumatology — 63 citations into it; #114 of 221 by trust here, #2 by citations
• Plant Science — 11 citations into it

Whom Brian J. Druker trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Andreas Hochhaus
2. H. Kantarjian
3. J. Goldman
4. M. Baccarani
5. C. Sawyers
6. M. Heinrich

Who trusts Brian J. Druker overall

1. F. S. Collins
2. Z. Du
3. Victor A. McKusick
4. J. Melo
5. J. Goldman
6. Michael R. Stratton
7. P. Cohen
8. M. Baccarani
9. Johanna Andrae
10. T. Hunter

Papers from Brian J. Druker's perspective

Ordered by how strongly the researchers Brian J. Druker trusts endorse each paper. Same corpus, a different order for every researcher.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Journal of Clinical Oncology)
2. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. (Cancer Cell)
3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. (The Lancet Oncology)
4. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
5. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. (Blood)
6. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. (Blood)
7. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. (Blood)
8. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Blood)
9. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. (Journal of Clinical Oncology)
10. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (Blood)

Their papers

• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (2001) — 5,221 citations
• Functional Genomic Landscape of Acute Myeloid Leukemia (2018) — 1,171 citations
• CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. (2011) — 777 citations
• Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia (2017) — 1,052 citations
• Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012) — 746 citations
• Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. (2011) — 799 citations
• AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. (2009) — 1,220 citations
• International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (2009) — 672 citations
• Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. (2008) — 654 citations
• Translation of the Philadelphia chromosome into therapy for CML. (2008) — 670 citations
• Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (2007) — 616 citations
• Chronic Myeloid Leukemia (2007) — 986 citations
• Gene expression changes associated with progression and response in chronic myeloid leukemia. (2006) — 609 citations
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (2006) — 3,470 citations
• In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. (2005) — 1,099 citations
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (2003) — 3,629 citations
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. (2003) — 2,287 citations
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy (2002) — 956 citations
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002) — 1,213 citations
• Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. (2002) — 672 citations